Compounds > 13,14-dihydroprostaglandin e1
Page last updated: 2024-09-04

13,14-dihydroprostaglandin e1 and n-formylmethionine leucyl-phenylalanine

13,14-dihydroprostaglandin e1 has been researched along with n-formylmethionine leucyl-phenylalanine in 1 studies

Compound Research Comparison

Studies
(13,14-dihydroprostaglandin e1)		Trials
(13,14-dihydroprostaglandin e1)		Recent Studies (post-2010)
(13,14-dihydroprostaglandin e1)		Studies
(n-formylmethionine leucyl-phenylalanine)		Trials
(n-formylmethionine leucyl-phenylalanine)		Recent Studies (post-2010) (n-formylmethionine leucyl-phenylalanine)
27236,71653356

Protein Interaction Comparison

ProteinTaxonomy13,14-dihydroprostaglandin e1 (IC50)n-formylmethionine leucyl-phenylalanine (IC50)
fMet-Leu-Phe receptorHomo sapiens (human)0.02

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Braun, M; Bruch, L; Ney, P; Schrör, K; Szymanski, C1

Other Studies

1 other study(ies) available for 13,14-dihydroprostaglandin e1 and n-formylmethionine leucyl-phenylalanine

ArticleYear
Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man.
    Eicosanoids, 1991, Volume: 4, Issue:3

    Topics: Alprostadil; Animals; Blood Platelets; Glucuronidase; Humans; In Vitro Techniques; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Platelet Activating Factor; Rabbits; Superoxides; Vasodilation

1991